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Despite similarities between tumor-initiating cells with stem-like properties (TICs) and normal neural stem
cells, we hypothesized that there may be differences in their differentiation potentials. We now demonstrate
that both bonemorphogenetic protein (BMP)-mediated and ciliary neurotrophic factor (CNTF)-mediated Jak/
STAT-dependent astroglial differentiation is impaired due to EZH2-dependent epigenetic silencing of BMP
receptor 1B (BMPR1B) in a subset of glioblastoma TICs. Forced expression of BMPR1B either by transgene
expression or demethylation of the promoter restores their differentiation capabilities and induces loss of
their tumorigenicity. We propose that deregulation of the BMP developmental pathway in a subset of glio-
blastoma TICs contributes to their tumorigenicity both by desensitizing TICs to normal differentiation cues
and by converting otherwise cytostatic signals to proproliferative signals.INTRODUCTION
A growing body of literature indicates that only a small subpopu-
lation of tumor cells are clonogenic and are capable of repopulat-
ing a tumor mass. These clonogenic cells have been found in
some tumor types to be highly undifferentiated with the capabil-
ity of both self-renewal and at least partial differentiation, similar
to tissue-specific normal stem cells, leading to their designation
as tumor stem cells (TSCs) or tumor-initiating cells with stem-like
properties (TICs) (Bonnet and Dick, 1997; Clarke et al., 2006;
Jordan et al., 2006; Reya et al., 2001). For example, several
groups have demonstrated the presence of TICs in various types
of primary brain tumors including glioblastomas (GBMs), epen-
dymomas, and medulloblastomas. These TICs have functional
similarities to normal NSCs, including their clonogenicity and
capability for multilineage differentiation (Hemmati et al., 2003;
Lee et al., 2006a; Singh et al., 2004; Taylor et al., 2005). Indeed,it has recently been reported that BMP acts as a key inhibitory
regulator of TICs from GBMs, similar to adult NSCs (Piccirillo
et al., 2006). Unlike normal stem cells, however, TICs harbor
the genetic aberrations characteristics of their representative
tumors (i.e., activation/amplification of oncogenes and loss of
tumor suppressor genes) endowing them with a tumorigenic
phenotype. A number of pathways that are commonly deregu-
lated in gliomagenesis, such as the NOTCH, epidermal growth
factor receptor (EGFR), and the mammalian target of rapamycin
(mTOR) pathways, are also involved in astrocytic differentiation
in normal NSCs (Hu et al., 2005; Purow et al., 2005; Sabatini,
2006; Viti et al., 2003), suggesting that differentiation pathways
of TICs may not be operated entirely similar to those of normal
NSCs. Nevertheless, exactly where along the developmental
pathway of tissue-specific stem cell maturation and differentia-
tion TICs arise and which, if any, of the intrinsic stem cell signal-
ing pathways are perturbed in TICs remains largely unknown.SIGNIFICANCE
Elucidation of the differentiation pathways operative and/or aberrant in both normal stem cells and TICs will be critical to
fully understand the pathogenesis of primary human tumors and may help lead to better therapies. To this end, we utilized
several TICs isolated from primary glioblastomas and compared them to normal human NSCs and mouse NSCs from var-
ious developmental stages. We demonstrate a major differentiation block in a subset of glioblastoma TICs is caused by the
Polycomb repressor complex (PRC)-mediated epigenetic silencing of theBMPR1B promoter, analogous to early embryonic
NSCs. We provide here an example of a temporally deregulated and aberrantly fixed developmental block to differentiation
contributing to the pathogenesis of a subset of human GBMs.Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc. 69
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Deregulated Differentiation in Glioblastoma TICsThe differentiation pathways of normal NSCs are complex and
differentially regulated by many cytokines. BMP-mediated PS-
SMAD1/5/8 pathways and CNTF-mediated Jak/STAT pathways
are the most widely studied cytokine-mediated pathways in the
differentiation of NSCs.
BMPs mediate a wide variety of biological responses in NSCs
ranging from proliferation to differentiation to apoptosis depend-
ing on the NSC developmental stage as well as the milieu of the
local microenvironments (Lim et al., 2000; Mehler et al., 2000).
The prototypic receptors for BMP 2/4 signaling in mammalian
brains are the type II receptor, BMPR2, and type I receptors,
BMPR1A and BMPR1B. One of best-characterized downstream
events following ligand binding is the activation of SMAD1/5/8 by
serine-phosphorylation. It has been reported that BMP2/4 acts
as a neuroepithelial proliferation signal at very early stages of em-
bryonic central nervous systemdevelopment, an effectmediated
principally by BMPR1A (Chen and Panchision, 2007; Panchision
et al., 2001). Later in development, BMP2/4 induces neuronal and
astrocytic differentiation of NSCs, an event coinciding with
increased expression of BMPR1B (Hall and Miller, 2004; Mehler
et al., 2000). The latter astroglial differentiation (E17-18 to murine
neonates) occurs within the context of acquisition of STAT3
responsiveness to CNTF/LIF (Bonni et al., 1997; He et al., 2005).
CNTF signaling pathways are largely restricted to astroglial
differentiation in NSCs. CNTF, a member of interleukin 6 super-
family including leukemia inhibitory factor (LIF), can transduce its
signal through the gp130 receptor complex and through the Jak
protein family, with subsequent activation of STAT3 by tyrosine
phosphorylation (PY-STAT3). Early embryonic NSCs are mini-
mally responsive to CNTF/LIF-mediated STAT3 activation. A sig-
nificant increase in the amount of STAT3 activation, either by
modulation of DNA demethylation, downregulation of specific
neurogenic transcription factors, and/or a feed-forward STAT3
activation signaling loop, seem to be required for the onset of
astrogenesis (He et al., 2005; Molne et al., 2000; Sun et al.,
2001; Takizawa et al., 2001).
In an effort to better understand the operative and aberrant
differentiation pathways in glioblastoma TICs, we utilized several
TIC-like cell lines isolated from primary glioblastomas, human
fetal brain-derived NSCs, and embryonic mouse NSCs isolated
from various developmental stages. We demonstrate here that
astroglial differentiation mediated by both the BMP- and CNTF-
mediated Jak/STAT pathway is impaired in TICs derived from
a subset of GBMs due to the epigenetic silencing of BMPR1B.
We provide an example of a temporally deregulated and aber-
rantly fixed normal stem cell developmental block to differentia-
tion contributing to the pathogenesis of a human tumor.
RESULTS
Deregulated Responses to BMP and CNTF Pathways
in 0308-TIC
We established various TICs from adult GBM patients. These
cells proliferate in the presence of FGF2 and EGF in serum-
free media and differentiate in the presence of serum or in the
absence of FGF2 and EGF. Transplantation of these cells into
brains of immunodeficient SCID mice generated tumors pheno-
copying the features of parental human GBM tumors (Lee et al.,
2006a). The results of our extensive single nucleotide polymor-70 Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc.phism (SNP) array-based genomic profiling and sequence ana-
lyses of genes implicated in the gliomagenesis demonstrate
that these TICs have genomic changes characteristics of typical
primary humanGBMs (Figure S1 availablewith this article online).
In order to evaluate cytokine-mediated differentiation of these
TICs, we performed in vitro differentiation assays (Figure 1 and
Figure S2). Since human NSCs isolated from various develop-
mental stages were not available, we utilized mouse NSCs
from various developmental stages extending from E10 brain-
derived neuroepithelial cells to adult subventricular zone (SVZ)-
derived NSCs. Spheroid-forming cells cultured in serum-free
media with FGF2 and EGF, the same conditions used for expan-
sion of various TICs (NBE condition) (Lee et al., 2006a), were dis-
sociated and plated in the polyornithine-coated plates for adher-
ent cultures. These cells were cultured in the presence of BMP2
or CNTF without FGF2 and EGF for 3 days and subsequently
processed for immunocytochemical staining (Figure 1A). All the
TICs continuously cultured in NBE condition retained their undif-
ferentiated state as assessed by both their morphology and
expression of Nestin and Sox2 (Figure 1A). Similar to other
TICs, withdrawal of FGF2/EGF induced differentiation of all of
our TICs lines as demonstrated by loss of Nestin and Sox2 (neu-
ral stem/progenitor markers) immunopositivity with concurrent
induction of GFAP (astroglial marker) or TuJ1 (neuronal marker)
expression. Most of the TICs lines cultured in the presence of
BMP2 or CNTF revealed further induction of differentiation as
determined by increased numbers of GFAP-positive cells (Fig-
ures 1A and 1B). BMP2-treated 0308 TICs, however, retained
their expression of Nestin and Sox2 and there was no significant
increase in the number of GFAP-positive cells. In addition,
GFAP-positive cells in CNTF-treated 0308 TICs are similar to
nontreated control, suggesting that 0308 TICs are relatively
insensitive to normal CNTF-mediated glial differentiation. Immu-
nostaining of CNTF-treated 0308 TICs for S100 b, another astro-
glial marker, revealed similar results (Figure S3).
Acutely isolated mouse NSCs from E11 brains differentiated
predominantly along a neuronal lineage upon exposure to
BMP2, while NSCs (passage 5) isolated from the SVZ of adult
brains differentiated mainly along an astroglial lineage (Molne
et al., 2000; Sun et al., 2001) (Figure S2). By contrast, CNTF treat-
ment failed to induce astroglial differentiation in E11 NSCs com-
pared to the efficient induction of astroglial differentiation in
adult-derived NSCs (Figure S2), in agreement with previous re-
ports (He et al., 2005; Molne et al., 2000). Thus, many TIC lines
have normal cytokine-induced differentiation responses similar
to adult-derived NSC, whereas 0308-TICs behave more like
E11 NSC cells (nonresponsiveness to CNTF), although they do
not demonstrate BMP-mediated neuronal differentiation. Taken
together, these data imply that 0308-TICs, unlike other TICs,
have defective/deregulated signal transduction responses to
the BMP and CNTF pathways, despite the fact that they retain
the ability to undergo terminal differentiation through the with-
drawal of growth factors and/or the addition of serum (Lee
et al., 2006a).
Downstream Effectors of BMP and CNTF Pathways
in Various TICs
In order to further understand the deregulated differentiation
pathways in 0308 TICs, we evaluated downstream effectors of
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Deregulated Differentiation in Glioblastoma TICsFigure 1. Immunohistochemical Analysis of Various TICs Cultured in the Presence of Differentiation-Inducing Cytokines
(A) Representative microphotographs of 0308 and 0822 TICs cultured in the presence of various cytokines. Each column represents the same culture condition.
(Aa–Ah) Immunohistochemistry of Nestin and Sox2 in 0308 TICs (Aa–Ad) and 0822 TICs (Ae–Ah). (Ai–Ap) Immunohistochemistry of GFAP and TuJ1 in 0308 TICs
(Ai–Al) and 0822 TICs (Am–Ap). DAPI staining (blue) was used to identify nuclei. White bars represent 10 micron.
(B) Differentiation potentials of various TICs after exposure to cytokines. Error bars represent SD (performed in triplicate). *p < 0.01.BMP and CNTF signaling in various TICs (Figure 2). Several
groups have recently demonstrated that brain TSC-like cells
are enriched in CD133-positive populations (Bao et al., 2006;
Singh et al., 2004). We isolated CD133+ cells from 0308 and0822 tumor cells by using fluorescence activated sorting
(FACS) and confirmed that, indeed, these cells are enriched in
tumorigenic potential in a SCID mouse transplantation model
(data not shown). Similar to normal human NSCs, BMP2 inducedFigure 2. Evaluation of Representative Acti-
vators of Jak/STAT and BMP Pathways in
Various TICs
(A) Western blot analysis of representative activa-
tors of Jak/STAT and BMP pathways in CD133+
TICs. Cells were stimulated with indicated cyto-
kines (50 ng/ml) for 20 min. PY-STAT3 indicates
detection of tyrosine 705-phosphorylated form of
STAT3. STAT3 indicates detection of all STAT3
proteins regardless of phosphorylation status.
PS-SMAD1/5/8 and SMAD1 indicate serine phos-
phorylated SMAD and total SMAD levels, respec-
tively.
(B and C) Western blot analysis of PY-STAT3 and
PS-SMAD1/5/8 in various TICs and normal human
NSCs (B) andmouseNSCs from different develop-
mental stages (C).
(D) Relative activation of PY-STAT3 and PS-
SMAD1/5/8 in various TICs and normal NSCs
upon cytokine exposure. Relative activation of
PY-STAT3 in a given condition was measured by
relative intensity of PY-STAT3 over that of STAT3
bands compared to nontreated control. Error
bars represent SD.Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc. 71
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Deregulated Differentiation in Glioblastoma TICsFigure 3. BMP Induces Proliferation Instead
of Differentiation of 0308 TICs
(A) Proliferation kinetics of various TICs in the pres-
ence of BMP2. Cells were cultured with BMP2
(without FGF2 and EGF) for 6 days. Cell number
(Aa) and BrdU-positive cells (Ab) were counted
and relative changes were calculated compared
to nontreated cells. Error bars represent SD.
(B) FACS analysis of BrdU incorporation in 0308
TICs. Percentages indicate BrdU-positive cells.
(C) Proliferation kinetics of mouse NSCs from dif-
ferent developmental stages. Error bars represent
SD.
(D and E) Western blot analysis of BMPR1B and
PY-STAT3 in serially cultured NSCs isolated from
E11 brains and adult-SVZ-derived mouse NSCs.
DIV represents days in vitro. GAPDH was used
to confirm equal loading of proteins.
(F) Quantitative mRNA expression level of
BMPR1B in various TICs and human NSCs deter-
mined by real-time RT-PCR analysis. Error bars
represent SD.strong activation of PS-SMAD1/5/8 in both 0308 and 0822
CD133+ cells. Similarly, CNTF induced strong activation of PY-
STAT3 in 0822 CD133+ cells (Figure 2A). By contrast, CNTF in-
duced only minimal activation of PY-STAT3 in 0308 CD133+
cells, consistent with the marginal CNTF-induced astroglial dif-
ferentiation observed in 0308 cells (Figures 1 and 2B). We further
examined the activation status of PS-SMAD1/5/8 and PY-STAT3
in additional TICs and normal NSCs isolated from both human
and mouse brains (Figures 2B and 2C). Normal human NSCs
(passage 15) and other TICs elicited strong activation of PS-
SMAD1/5/8 and PY-STAT3 upon BMP2 and CNTF challenge,
respectively. In addition, adult mouse brain-derived NSCs re-
spond to BMP and CNTF by showing a clear induction of PS-
SMAD1/5/8 and PY-STAT3, respectively (Bonni et al., 1997; He
et al., 2005). By contrast, mouse NSCs acutely isolated from ear-
lier embryonic stages (E10 to E11) did not elicit CNTF-triggered
PY-STAT3 activation, consistent with previous reports (He
et al., 2005; Sun et al., 2001) (Figure 2C). In order to further con-
firm the activation status of the BMP andCNTF pathways in 0308
TICs, we performed real-time RT-PCR analysis of genes known
to be upregulated through these pathways. Following exposure
of 0308 TICs to BMP2, we found clear induction of genes down-
stream of the SMAD pathway including Id1, Id3, and Hes1, con-
sistent with the observed PS-SMAD1/5/8 activation (Massague
et al., 2005; Ying et al., 2003). By contrast, CNTF induced little
activation of genes downstream of the Jak/STAT pathway, in-
cluding SOCS3 and JunB (data not shown) (Passegue et al.,
2004). Taken together, these data suggest that the unique BMP
response observed in 0308 TICs is unlikely attributed to subopti-
mal activation of PS-SMAD1/5/8, whereas the lack of CNTF re-
sponse is due, at least in part, to the failure to activate PY-STAT3.
BMP Induces Proliferation Instead of Differentiation
of 0308 TICs
The inability of BMP2 to induce differentiation in 0308 TICs is
reminiscent of its effects on early embryonic NSC where BMP72 Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc.acts as a transient mitogen (Chen and Panchision, 2007; Liu
et al., 2004). Thus, we explored the mitogenic properties of
BMP2 on various TICs. Proliferation kinetics determined both
by cell number counting and BrdU incorporation assays (Figures
3A–3C) demonstrated that BMP2 treatment of 0308 cells signifi-
cantly increased BrdU incorporation and the total number of
cells by day 4, similar to its effects on E11 NSC (Figure S4). By
contrast, BMP2 caused no significant increase in proliferation
or BrdU uptake in other TIC lines or in adult NSCs (Figures 3A
and 3C). In order to determine whether this mitogenic effect
of BMP2 on 0308 TICs can be reflected by clonogenicity, we per-
formed sphere-forming assays by using single-cell dissociated
TICs (Figure S5). BMP-treated 0308 cells showed the enhanced
clonogenic sphere formation, albeit lower than FGF2/EGF-
treated cells.
In early embryonic NSCs, BMP signaling leads to both
NSC proliferation and neuronal differentiation. This pleiotropic
response may, in part, be due to the differential expression
of the BMP receptor subtypes.Whereas BMPR1A is ubiquitously
expressed in most NSCs, BMPR1B expression increases
through the developmental maturation process of NSCs. Upon
BMP signaling, BMPR1B expression is transcriptionally induced
by BMPR1A-mediated PS-SMAD1/5/8 activation. Therefore,
it has been proposed that early neural precursor cells express
mainly BMPR1Awhereas NSCs from later developmental stages
to the adult stage express both BMPR1A and BMPR1B. Accord-
ingly, BMPR1A-mediated signals may be mainly responsible for
proliferation of early NSCs whereas BMPR1B-mediated signals
likely play a role in NSC differentiation and survival. Thus, we
examined the status of the BMPR subtypes in normal embryonic
NSCs. Compared to adult SVZ-derived NSCs, acutely isolated
E10-E11 neuroepithelial cells have very low levels of BMPR1B
expression; however, these cells showed progressive expres-
sion of BMPR1B following several days in culture (i.e.,
intrinsic cellular developmental clock; Figure 3D). Similarly to
the 0308 TICs, neuroepithelial cells acutely isolated from E11
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Deregulated Differentiation in Glioblastoma TICsFigure 4. Overexpression of BMPR1B in 0308-TICs Enhances Astroglial Differentiation
(A) Proliferation kinetics of BMPR1B-0308 cells cultured in BMP2 and CNTF (without FGF2 and EGF). Error bars represent SD.
(B) Western blot analysis of representative activators of Jak/STAT and BMP pathways in 0308 and BMPR1B-0308 cells treated with indicated cytokines (BMP2,
50 ng/ml; CNTF, 50 ng/ml; LIF, 100 ng/ml). Exogenous BMPR1B expression was monitored by expression of HA tag, which was fused with BMPR1B protein.
(C) Increased astroglial differentiation in 0308-BMPR1B cells. (Ca) Representative immunohistochemical staining of BMPR1B-0308 cells cultured in the presence
of BMP2 or CNTF (50 ng/ml each). Cytokines were added every other day (in the absence of FGF2 and EGF) for 5 days. White bar represents 10 micron. (Cb)
Quantitation of Sox2 and GFAP-positive cells in (Ca). Error bars represent SD.
(D) Transcriptional activity assay of synthetic STAT3-responsive promoter (Da) and genomic GFAP promoter (Db) in 0308 cells and human NSCs. Cells were
cotransfected with a plasmid containing a STAT3-responsive or genomic GFAP promoter-driving luciferase expression and a plasmid containing a CMV pro-
moter-driving beta-galactosidase expression. y axis represents relative activity of luciferase versus beta-galactosidase activity. Error bars represent SD.
(E) Quantitation of GFAP-positive cells after modulation of STAT3 activity in 0308 and 0308-BMPR1B cells. Cells were transiently transfected with either empty
vector control, STAT3D, or STAT3C vectors and processed for GFAP staining 4 days after transfection. Percent of GFAP-positive cells among transfected cells
are shown. Data shown were from a representative experiment and numbers in parentheses represent SD.
(F) Western blot analysis of PY-STAT3 and PS-SMAD1/5/8 in tetracycline-inducible U251-BMPR1B cells. Cells were serum starved overnight prior to the
addition of various cytokines (B, BMP2; T, TGF-b; C, CNTF; L, LIF). Actively proliferating U251 or U251-BMPR1B cells in serum-containing media reveals
PY-STAT3 (right).embryos demonstrated only marginal PY-STAT3 activation fol-
lowing CNTF challenge; however, after in vitro passage over sev-
eral days, the NSCs ultimately demonstrated significantly high
CNTF-mediated PY-STAT3 activation, comparable to that seen
in adult NSCs (Figures 2C and 3E). Thus, the timing of BMPR1B
expression in embryonic NSCs correlates with the induction of
PY-STAT3 activation, events that occur immediately before the
onset of increased potential for astroglial differentiation.
Given the similarity between 0308-TICs and early embryonic
NSCs, we examined the expression of the BMPR subtypes
in different TIC lines. Expression levels of BMPR2 and BMPR1A
in various TICs were comparable as determined by real-time RT-
PCR analysis and western blot analysis (Figure S6). By contrast,
BMPR1B expression was almost totally lacking in 0308-TICs
compared to normal NSCs and other TICs (Figure 3F). Based
on these data, we hypothesized that the lack of BMPR1B ex-
pression might be responsible for both the lack of CNTF-depen-
dent PY-STAT3 activation and the aberrant BMP-mediated pro-
liferation/differentiation responses observed in 0308-TICs.Expression of BMPR1B in 0308 TICs Abolishes BMP-
Induced Proliferation and Renders Them Responsive
to CNTF
In order to test our hypothesis, we overexpressed a constitutively
active BMPR1Bmutant protein in 0308-TICs (Figure 4). This con-
struct was generated by a point mutation in the glycine/serine
domain of BMPR1B leading to constitutive phosphorylation of
PS-SMAD1/5/8, albeit with low efficiency (Panchision et al.,
2001). Polyclonal populations of BMPR1B-expressing TICs pro-
liferated slower than the control transfected or parental 0308-
TICs, however, still maintained expression of stem cell markers
and clonogenicity in vitro, suggesting that BMPR1B expression
itself is not sufficient to induce differentiation of the 0308 TIC un-
der proliferation-conducive culture conditions (NBE condition)
(data not shown). We then evaluated the proliferation kinetics
of BMPR1B-0308 cells in the presence of BMP2. Unlike the
parental and transfection control cells, BMP2 did not induce
proliferation nor enhance clonal sphere formation in BMPR1B-
overexpressing cells (Figure 4A and Figure S5).Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc. 73
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Deregulated Differentiation in Glioblastoma TICsNext, we examined main effectors of BMP2- and CNTF-medi-
ated signal transduction pathways in these cells. The basal levels
of PS-SMAD1/5/8 in BMPR1B-overexpressing 0308 cells
were similar or slightly higher than the parental cells; however,
BMPR1B-overexpressing cells significantly upregulated phos-
phorylation of STAT3 following exposure to CNTF/LIF
(Figure 4B and Figure S7). We then evaluated the effects of
BMPR1B overexpression on cytokine-mediated differentiation
of 0308 TICs (Figure 4C). After 5 days of culture in the presence
of BMP2, BMPR1B-overexpressing cells demonstrated a more
differentiated morphology than BMP-treated 0308 TICs (Fig-
ure 4C). Furthermore, BMP2 induced a dramatic downregulation
in Sox2 and a significant upregulation in GFAP expression
in BMPR1B-overexpressing 0308 TICs, similar to the response
of adult-derived normal NSCs (Figure 4C). Finally, CNTF treat-
ment of 0308-BMPR1B cells significantly increased the number
of GFAP /S100b-positive cells consistent with the robust induc-
tion of PY-STAT3 in the BMPR1B-treansfected 0308 cells (Fig-
ures 4B and 4C and Figure S3).
Increased Astroglial Differentiation Potential
by BMPR1B Overexpression Is Mediated
by PY-STAT3 Activation
In order to confirm PY-STAT3 activity following exposure of
0308-BMPR1B cells to CNTF, we performed transcription re-
porter assays using a synthetic STAT3 responsive promoter (Fig-
ure 4D). Indeed, transcriptional activity of PY-STAT3 was sig-
nificantly increased in 0308-BMPR1B cells following CNTF
exposure compared to the parental 0308 cells. Additionally,
CNTF treatment activated transcription from a genomic GFAP
promoter in 0308-BMPR1B cells, consistent with the known
temporal association between phosphorylation and activation
of PY-STAT3 and astrocytic differentiation (Figure 4D). It has
been reported that CNTF-triggered STAT3 phosphorylation is
critical for astrocytic differentiation of normal NSCs (He et al.,
2005). To evaluate the importance of STAT3 activity on astro-
cytic differentiation of 0308 cells, we modulated STAT3 activity
by overexpressing either a dominant negative form of STAT3
(STAT3D) or a constitutively active form of STAT3 (STAT3C)
(Bromberg et al., 1999). Inhibition of STAT3 activity in
BMPR1B-0308 cells decreased the number of GFAP-positive
cells after CNTF treatment (Figure 4E), suggesting that STAT3
activity is necessary for accelerated astrocytic differentiation.
Overexpression of STAT3C alone in 0308 cells, however, did
not increase the number of GFAP-positive cells, indicating that
additional factors appear to be required for astroglial differentia-
tion of 0308 cells (Viti et al., 2003).
To explore whether overexpression of BMPR1B can cause
a general activation of the Jak/STAT pathways leading to glial dif-
ferentiation or an antiproliferative effect in any glioma cell line, we
overexpressed BMPR1B in a standard U251 glioma non-stem
cell line. Like most glial tumor cell lines, U251 cells have high
basal PY-STAT3 activity when cultured in serum-containing me-
dia; however, they did not elicit detectable CNTF-triggered PY-
STAT3 activation (Figure 4F) (Haura et al., 2005; Schaefer et al.,
2000). Forced expression of BMPR1B in U251 cells did not in-
duce modulation of STAT3 phosphorylation or STAT3 activity af-
ter CNTF challenge (Figure 4F). Furthermore, the in vitro growth
kinetics and in vivo tumorigenic potential of U251 cells were74 Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc.not changed following overexpression of BMPR1B (data not
shown), arguing against the importance of BMPR1B effects on
tumor cell growth or differentiation in a non-stem cell setting.
Taken together, these data suggest that BMPR1B overexpres-
sion enhances the astrocytic differentiation potential of 0308
TICs in a STAT3-dependent, but not sufficient, manner.
BMPR1B Overexpression Decreases Tumorigenicity
of 0308 Cells through Induction of Glial Differentiation
Given the phenotypic and functional changes we observed in
0308-BMPR1B cells in vitro, we next tested whether BMPR1B
overexpression affects the tumorigenicity and in vivo differentia-
tion potential of 0308 cells by using a neonatal SCID mouse or-
thotropic tumor model (Figure 5). Mice undergoing intracerebral
injection of 0308 cells die within 2 to 3 months of a diffusely infil-
trating glioma histologically identical to human GBMs. By con-
trast, most mice (5 of 7) injected with 0308-BMPR1B cells did
not develop detectable tumors even after 5 months of observa-
tions. The brains of mice injected with either control 0308 cells or
0308-BMPR1B cells were examined at various time points by
immunohistochemical analysis (Figure 5A). Far fewer intracranial
0308-BMPR1B cells were seen compared to the parental 0308
cells at both 40 and 60 days following intracranial injection (Fig-
ures 5A and 5B). Distinct tumor masses were detected near the
ventricular walls and cortices of mice injected with 0308 cells as
early as the 40 day time point (Figure 5A). By contrast, 0308-
BMPR1B cells weremainly detected in the ventricles and corpus
callosum and did not form distinct tumor masses (Figure 5A).
Immunohistochemical analysis using Sox2 and human specific
antibodies revealed a significantly lower number of Sox2-posi-
tive human cells in brains injected with 0308-BMPR1B cells,
compared to those injected with parental 0308 cells (Figures
5A and 5B). In order to quantitatively evaluate the differentiation
status of both 0308- and 0308-BMPR1B-derived tumors, we iso-
lated individual intracerebral tumor cells by FACS sorting and
determined their level of GFAP expression. Compared to the
0308 cells, a higher percentage of 0308-BMPR1B cells (about
1.7-fold) expressed GFAP and did so with a higher expression
intensity (Figure 5C). These findings are consistent with a greater
tendency for 0308-BMPR1B cells to undergo spontaneous dif-
ferentiation in vivo compared to the parental 0308 cells, thereby
resulting in significantly prolonged survival in mice injected intra-
cerebrally with 0308-BMPR1B cells compared to mice with the
parental 0308 cells (Figure 5D).
Expression of BMPR1B in 0308 TICs Is Silenced by
Hypermethylation of BMPR1B Promoter and Restored
by Demethylation or Knockdown of EZH2
In an attempt to elucidate the mechanism responsible for the
lack of BMPR1B expression in 0308 TICs, we sequenced both
the BMPR1B cDNA and its corresponding exons in genomic
DNA. No mutations were detected. We, therefore, explored a
potential epigenetic mechanism for the diminished BMPR1B
mRNA expression. DNA hypermethylation, especially in CpG
islands, is a major epigenetic mechanism utilized by tumor cells
to inactivate tumor suppressor genes and/or tumor susceptibility
genes (Widschwendter et al., 2007). Intriguingly, it has been
demonstrated that DNA methylation is a critical cell-intrinsic de-
terminant of astrocytic differentiation of NSCs in the mouse fetal
Cancer Cell
Deregulated Differentiation in Glioblastoma TICsbrain (Takizawa et al., 2001). Forced demethylation/hypomethy-
lation of early embryonic neuroepithelial cells by treatment with
5-aza-20-deoxycytidine (Aza-Cd) or genetic knockout of DNA
methyl transferase 1 (DMNT1) has been shown to induce preco-
cious astrocytic differentiation in the embryonic mouse brain
(Fan et al., 2005; Takizawa et al., 2001). The human BMPR1B
gene contains distinct CpG islands at the near 50 transcription
start site, which are conserved in other mammalian genomes in-
cluding mouse. Thus, we explored the possibility of aberrant
methylation of the BMPR1B promoter in 0308 cells. Bisulfite
modification of genomic DNA and subsequent sequence analy-
sis revealed that, in contrast to those in normal human NSCs and
normal human fetal astrocytes, the CpG islands of BMPR1B
gene were heavily methylated in 0308-TICs (Figure 6A). Treat-
ment of 0308 cells with Aza-Cd caused demethylation of the
BMPR1B promoter and significantly increased expression of
BMPR1B mRNA (Figures 6A and 6B). Additionally, within 2.5
days of Aza-Cd treatment, CNTF-mediated PY-STAT3 phos-
phorylation was restored to levels seen in normal NSCs leading
to the increased astrocytic differentiation of 0308 TICs
(Figure 6C). Similarly, mouse E11 neuroepithelial cells treated
with Aza-Cd also demonstrated a dramatic increase in BMPR1B
expression, acquired CNTF-mediated STAT3 activation, and
underwent precocious astrocytic differentiation (Figure S8).
Thus, the biological effects of demethylation seen in 0308 TICs
are mirrored by those observed in E11 NSC.
The data presented above support the hypothesis that at least
one of the mechanisms responsible for the failure of 0308-TIC
cells to express BMPR1B involves deregulated methylation/de-
methylation of the BMPR1B promoter. Interestingly, human
embryonic stem (ES) cells also do not express BMPR1B due to
Polycomb repressor complex (PRC)-mediated transcriptional
Figure 5. Overexpression of BMPR1B in
0308 Cells Decreased Tumorigenicity
In Vivo
(A) Representative immunohistochemistry of tu-
mors derived from 0308 and 0308-BMPR1B cells
at 40 days (Aa–Ac and Af–Ah) and 60 days (Ad,
Ae, Ai, and Aj). Note that GFAP antibody recog-
nizes both human and mouse GFAP proteins. In-
set in (Ae) demonstrates immunostaining of Sox2
(green) and GFAP (red). DAPI staining (blue) was
used to reveal anatomic locations in brains. White
bars represent 100 micron.
(B) Quantitation of Sox2-positive cells in tumors
derived from 0308 and 0308-BMPR1B cells. SVZ
and CTX indicate subventricular zones and cortex,
respectively. Error bars represent SD.
(C) FACS analysis of GFAP expression in 0308-
and 0308-BMPR1B-derived tumor cells.
(D) Survival of animals injected with 0308 (n = 8)
and 0308-BMPR1B cells (n = 7) (log rank test:
p < 0.001).
repression (Lee et al., 2006b). In addition,
recent papers have demonstrated that
Enhancer of Zeste homolog 2 (EZH2),
a key component of PRC2/3 complex, fa-
cilitates CpG methylation of EZH2-target
promoters by recruiting DNA methyl-
transferases (DNMTs) and is highly expressed in various tumors
as well as normal stem cells (Valk-Lingbeek et al., 2004; Vire
et al., 2006). Indeed, we detected robust expression of EZH2 in
all TICs we examined (Figure S9).
In order to determine whether BMPR1B expression in 0308
TICs is under the control of PRC-mediated transcriptional
repression similar to human ES cells, we performed chromatin
immunoprecipitation (Chip) analysis (Figure 6D). The significant
association of RNA polymerase II with the BMPR1B promoter
in 0822 cells, but not in 0308 cells, is consistent with the relative
expression levels of BMPR1B mRNA in these two cell lines.
BMPR1B promoter DNA from 0308 cells, but not from 0822 cells,
was coimmunoprecipitated by both anti-EZH2 and anti-DNMT1
antibodies, implicating the possibility of physical association of
PRC2/3 complexes and DNMTs with BMPR1B promoter DNA
in 0308 cells (Figure 6D). Next, we examined whether this asso-
ciation contributes to the hypermethylation of the BMPR1B
promoter and its low expression in 0308 cells by using small
interference RNA (siRNA) against EZH2 (Figure 6E). Compared
to control siRNA-treated cells, EZH2 siRNA-treated cells dem-
onstrated a significant increase in BMPR1B expression. Further-
more, bisulfite genomic sequencing revealed that the CpG
nucleotides in the BMPR1B promoter region were significantly
less methylated in EZH2 siRNA-treated 0308 cells compared
to control cells, suggesting that the lack of BMPR1B expression
in 0308 cells is due to Polycomb-mediated transcriptional
repression via CpG methylation of the BMPR1B promoter.
Expression of BMPR1B and Methylation Status of Its
Promoter in Primary Human Glioblastoma Tissues
The above data suggest that functional loss of BMPR1B expres-
sion in 0308 TICs may contribute to gliomagenesis throughCancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc. 75
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Knockdown of EZH2
(A) Methylation sequencing of BMPR1B promoter region in various cells. (Aa) The diagram depicts the predicted CpG islands near the BMPR1B promoter region
(Li and Dahiya, 2002). The transcription start site of BMPR1B (indicated by arrow; designates as 1 in this diagram) is base pair 96036306 on chromosome 4
(Genome Browser). Each CpG nucleotide is depicted as a red vertical line. (Ab) Methylation status of CpG islands by bisulfite genomic sequencing. Each circle
represents a CpG nucleotide site. Filled circles indicate methylated CpG. Percentage of methylated clones (more than 25% of CpG sites are methylated) was
calculated from 16 individual clones for each cell.
(B) Real time RT-PCR analysis of BMPR1B expression in 0308 TICs and normal cells. Relative expression level of BMPR1B was evaluated by Ct method. Error
bars represent SD (performed in triplicate).
(C) Increased astroglial differentiation of 0308 TICs treated with Aza-Cd. (Ca) Western blot analysis of PY-STAT3 and PS-SMAD1/5/8 in 0308 cells treated with
Aza-Cd. GAPDHwas used as a loading control. (Cb) Representative immunostainingmicrophotographs of 0308 cells with or withour Aza-Cd treatment.White bar
represents 10 micron.
(D) Chromatin immunoprecipitation of BMPR1B promoter region in 0308 and 0822-TICs. Antibodies used for immunoprecipitation are shown above. DNA
products shown in the lower row served as PCR efficiency control.
(E) Expression of BMPR1B and methylation status of its promoter in EZH2 siRNA-treated 0308 TICs. (Ea) Western blot analysis of EZH2 expression in EZH2
siRNA-treated 0308 cells. Three days after siRNA treatment, cells were harvested for analysis. Actin was used as a loading control. (Eb) Real-time RT-PCR
analysis of EZH2 and BMPR1B mRNA expression in EZH2 siRNA-treated 0308 TICs. Error bars represent SD (performed in triplicate). (Ec) Methylation status
of the BMPR1B promoter region in EZH2 siRNA-treated 0308 cells as determined by a methylation-specific PCR assay. M, methylated; U, unmethylated;
C, control PCR primers. (Ed) Bisulfite genomic sequencing analysis for CpG methylation following knockdown of EZH2. Each line is the result from an individual
clone.expansion of either a pre-TSC or TSC population via BMP-medi-
ated proliferation and/or block to terminal differentiation through
an aberrant Jak/STAT response to CNTF/LIF. In order to address
whether this phenomenon occurs in primary glioblastomas in
situ, we performed real-time RT-PCR for the purpose of deter-
mining the relative frequency ofBMPR1BmRNA downregulation
in primary human GBMs (Figure S10). A total of 54 glioblastomas
were evaluated, of which 10 (18.5%) demonstrated significant
reduction (more than 3-fold) ofBMPR1BmRNA expression com-
pared to the nontumor-bearing cerebral cortex samples (n = 6).
By contrast, 12 samples (about 22%) of primary tumors showed
significant overexpression (more than 3-fold) of BMPR1B com-
pared to normal cortex. We sequenced the BMPR1B cDNAs
and corresponding genomic regions from these 12 glioblasto-
mas that did not haveBMPR1B downregulation in order to deter-
mine whether any of these DNAs harbor mutations, but found
none. Thus, it appears that BMPR1B downregulation is found76 Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc.in approximately 20% of glioblastomas. Bisulfite genomic se-
quencing of the BMPR1B promoter region in a set of primary
glioblastoma samples demonstrated significant hypermethyla-
tion of the promoter region in 6 of 7 tumors with significant reduc-
tion of BMPR1B mRNA (85%). By contrast, nontumor-bearing
brain tissues (n = 4) and tumors without BMPR1B downregula-
tion (n = 5) did not show any hypermethylation in CpG islands
of BMPR1B gene (Figure 7A). Correlation of expression level of
BMPR1B and methylation status of its promoter in the various
glioblastomas was highly significant (p < 0.01). These data
suggest that BMPR1B downregulation seen in a subset of pri-
mary GBMs is mainly due to epigenetic silencing due to CpG
methylation in the BMPR1B promoter region as was seen in
the 0308 TICs. Finally, the median expression of GFAP in glio-
blastoma specimens with low BMPR1B expression was signifi-
cantly lower than that seen in all other glioblastomas, consistent
with a relative block to astroglial differentiation in situ in this
Cancer Cell
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Promoter in Human GBMs
(A) Methylation status of the BMPR1B promoter
region in human GBMs. Each circle represents
CpG nucleotides. The extent of CpG methylation
(%) and frequency of methylated clones were
determined as shown in Figure 6. Eight clones
for each sample were sequenced.
(B) Correlation between the mRNA expression
level of BMPR1B and GFAP in a subset of human
GBMs. Expression levels ofGFAPwere compared
between the BMPR1B-low mRNA expression
group (defined as GBMs with more than 3-fold re-
duction in median BMPR1B expression compared
to all other GBMs) and all other GBM tissues.
Median GFAP expression value was shown as a
horizontal line. (two-tailed t test; p < 0.0027).subset of glioblastoma as demonstrated in 0308 TICs (Figure 7B
and Figure S11).
DISCUSSION
A number of recent reports have identified clonogenic cancer
cells with stem-like properties from various primary human epi-
thelial tumors including those of the breast, colon, prostate, pan-
creas, and brain (Liu et al., 2005; O’Brien et al., 2007; Ricci-Vitiani
et al., 2007; Singh et al., 2004). These studies have shown that
these stem-like cells have clonogenic and tumorigenic capacity,
as well as have phenotypes and functional properties similar to
tissue-specific stem cells. Several studies have also demon-
strated that these TSCs have genetic and gene expression pat-
terns similar to those of the primary tumors (Lee et al., 2006a;
Taylor et al., 2005). One recent report demonstrated that a few
glioma-derived TICs differentiate in response to BMP, similar
to what is seen in NSCs, adding to the growing data implicating
a stem cell origin for malignant gliomas. Nevertheless, there have
been few, if any, reports demonstrating exactly where along the
developmental pathway of tissue-specific stem cell maturation
and differentiation TSC arise, and which, if any, of the intrinsic
stem cell signaling pathways are perturbed in TSC remains
largely unknown.
Our data demonstrate that 0308 TICs, although isolated from
adult patient, are significantly more similar to early embryonic
NSCs (i.e., E11 mouse NSCs) than to later embryonic or adult-
brain-derived NSCs. These similarities include a transient mito-
genic response to BMP ligands, lack of BMPR1B expression
secondary to promoter hypermethylation, little or no PY-STAT3
activation following CNTF/LIF exposure, and delayed astroglial
differentiation. In contrast to early embryonic NSCs, however,
0308-TICs do not spontaneously acquire BMPR1B expression
nor develop responsiveness to CNTF/LIF-mediated STAT3
phosphorylation over time and/or serial passages in vitro.
Thus, 0308 TICs appear be perpetually stuck at a developmental
point similar to that of early embryonic NSCs, at least in part, due
to aberrant genomic methylation as seen in other tumors (Bern-
stein et al., 2007; Jones and Baylin, 2007; Schlesinger et al.,2007). The precise reasons why 0308-TICs cannot proceed
through their methylation-associated BMPR1B-dependent de-
velopmental block in vitro (and presumably in vivo) is not fully
clear. Possibilities include aberrations in oncogenic pathways
implicated in both developmental and glioma biology (e.g.,
EGFR, PTEN, and mTOR) or other stem cell pathways (Kama-
kura et al., 2004). Potential interactions between these funda-
mental pathways clearly warrant further investigation. Regard-
less of the mechanism, however, lack of BMPR1B expression
appears to be mechanistically responsible for the failure of
0308 TICs to efficiently differentiate. Support for this contention
is based on our observations that overexpression of BMPR1B
cDNA in 0308 cells leads to decreased BMP2-mediated mito-
genic effects, STAT3 responsiveness to CNTF/LIF exposure, in-
creased astroglial differentiation, and loss of TIC tumorigenicity
in vivo.
CNTF signaling pathways are believed to be restricted to
astroglial differentiation in brain cells. As has been previously re-
ported and demonstrated here, early embryonic NSCs are less
responsive to CNTF/LIF-mediated STAT3 activation. Although
there is debate regarding the relative amount of STAT3 activation
in early NSCs (He et al., 2005; Molne et al., 2000; Takizawa et al.,
2001), a clear increase in the amount of STAT3 activation either
bymodulation of DNA demethylation, downregulation of specific
neurogenic transcription factors, and/or a feed-forward STAT3
activation signaling loop seems to be required for the onset of
astrogenesis. We have shown that CNTF/LIF-mediated STAT3
activation is impaired in 0308-TICs and can be restored by over-
expression of BMPR1B, suggesting a causal role of BMPR1B
induction in the Jak/STAT pathways and astroglial differentiation.
Further studies are ongoing in order to elucidate the underlying
molecular mechanisms between BMP and Jak/STAT signaling
in early embryonic NSCs.
STAT3 activation is critical for maintenance of stem cell func-
tion, differentiation, and survival (Levy and Darnell, 2002). Over-
activation of STAT3 has been reported to be oncogenic in various
model systems and is frequently observed in various tumor types
(Bromberg et al., 1999). For example, tyrosine phosphoryla-
tion-mediated STAT activation can be induced by EFGR/Src,Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc. 77
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et al., 1998). Notch and mTOR pathways also have been
reported to activate this pathway (Hu et al., 2005; Kamakura
et al., 2004). By contrast, our data suggest that although not
sufficient, a relative increase in the level and/or timing of STAT3
activation by CNTF is necessary for astroglial differentiation of
0308 TICs. Thus, STAT3 activation can be cytostatic as well as
pro-proliferative. The likely explanation for this seemingly para-
doxical behavior of STAT3 activation is that the STAT pathway
is context-dependent and various intracellular aswell as environ-
mental cues play a pivotal role in determining the outcome of
pathway activation. In addition, a recent report has demon-
strated that STAT3 serine phosphorylation in addition to, or in
lieu of, tyrosine phosphorylation is critical to stem cell survival,
further emphasizing the complexity of this pathway (Androutsel-
lis-Theotokis et al., 2006). Finally, previous studies have largely
relied on traditionally grown and established cancer cell lines
where STAT3 and other signaling pathwaysmay have very differ-
ent functions than they do in primary human tumor-derived TICs
and NSCs (Schaefer et al., 2000).
One unresolved, yet intriguing, question is precisely how and
to what extent the BMPR1B-associated developmental block
contributes to tumorigenesis. It had been once believed, based
largely on the leukemia model of cancer, that all tumor cells
were dedifferentiated cells with complete clonogenic capacity.
A block in differentiation was, therefore, essentially the cause
of the cancer resulting in uncontrolled proliferation of each and
every cell (i.e., the tumor was essentially a mass of accumulating
tumor stem/initiating cells). It is increasingly clear, however, that
in epithelial cancers like glioblastoma, TSC/TICs generally repre-
sent a minor component of the bulk of tumor tissue with the ma-
jority of tumor consisting of more differentiated progeny of TSC/
TICs with limited clonogenicity (as was the case for the tumor
from which the 0308 cells were derived from; data not shown).
Thus, a relative block in capacity for TSC differentiation, such
as seen in the 0308 cells, could contribute to tumorigenesis
through the maintenance of a nondifferentiated and hence self-
renewing TSC population readily available to generate progeny
that make up the bulk of the tumor under conditions that would
otherwise lead to differentiation of that TSC. An alternative ex-
planation, however, is that the inhibition of BMPR1B expression
in 0308 TICs and a subset of primary glioblastomas may have
less to do with blocking terminal differentiation and more to do
with expansion of the clonogenic stem cell population through
the mitogenic effects of BMP2/4, as we have demonstrated in
0308 TICs. This is certainly plausible given the well-documented
presence of BMP 2/4 throughout the normal and injured adult
brain. This is consistent with work by others and us demonstrat-
ing that malignant gliomas express higher levels of BMP2/4 than
lower grade gliomas or normal cerebral tissue, thereby poten-
tially setting up an autocrine feedback loop for BMP-mediated
TSC/TIC proliferation (Liang et al., 2005) (data not shown). Fur-
ther work is required to determine the relative contribution of
these two, non-mutually exclusive, mechanisms of TSC/TIC-
mediated tumorigenesis.
Epigenetic changes, such as hypermethylation of CpG islands
in promoter regions and altered profiles of histone modification,
are now recognized to be likely major contributors to tumorigen-
esis in a number of different cancers (Schlesinger et al., 2007;78 Cancer Cell 13, 69–80, January 2008 ª2008 Elsevier Inc.Trojer and Reinberg, 2006). Polycomb group (PcG) proteins are
essential components by which stem cells reversibly repress
genes related to differentiation (Sparmann and van Lohuizen,
2006). Recently, it has been reported that PcG target genes
are much more likely to have promoter hypermethylation in can-
cer than nontarget genes (Widschwendter et al., 2007). We have
shown that hypermethylation of the BMPR1B gene in 0308 cells
and a subset of primary glioblastomas is mechanistically linked
to EZH2, a key component of PRC2/3 complex. Interestingly,
the BMPR1B gene is a PRC target gene and is transcriptionally
repressed in undifferentiated human ES cells. These observa-
tions, taken together with the data presented here, lead us to hy-
pothesize that 0308 TICs and a corresponding subset of primary
glioblastomas have an aberrant NSC developmentally regulated
demethylation program that results in the failure to induce
BMPR1B expression and leads to a selective block in TSC/
TIC/stem cell differentiation. This is entirely consistent with the
idea that the normal, developmentally-regulated, reversible re-
pression of differentiation-inducing genes is replaced by their
permanent silencing in cancers, thereby favoring a perpetual
stem cell state (Widschwendter et al., 2007).
We propose that lack of BMPR1B expression in a tumor stem
cell population contributes to the differentiation block in a subset
of primary human glioblastomas. We hypothesize that other glio-
blastomas likely have different aberrant differentiation/prolifera-
tion pathways unique to their corresponding TIC populations.
Therefore, we do not necessarily believe that BMPR1B-deficient
GBMs are ‘‘more tumorigenic’’ than other GBMs with normal or
high levels of BMPR1B or that BMPR1B expression has a partic-
ular prognostic significance. Rather, the identification of a subset
of glioblastomas that has this particular differentiation block will
be of great utility for further understanding glioma pathophysiol-
ogy, cancer stem cell biology, and for ultimately designing ratio-
nale therapeutic strategies targeted to tumors with the appropri-
ate biology. One example is our finding that Aza-Cd-mediated
demethylation of the BMPR1B promoter leads to upregulation
of BMPR1B and terminal astrocytic differentiation of 0308
TICs. Since Aza-Cd is currently being evaluated in clinical trials
of various tumors, as are other demethylating and chromatin
modulating agents, our data demonstrate that such agents
may be particularly useful for patients with glioblastomas harbor-
ing hypermethylation-mediated transcriptional repression of
BMPR1B. These observations, therefore, identify BMPR1B as
a promising molecular therapeutic target in a subset of glioblas-
tomas worthy of further development. Likewise, the suggestion
that BMP2/4 might be explored as a potential therapeutic agent
through its ability to induce differentiation in some glioma-de-
rived TICs must be viewed with caution given our demonstration
of the mitogenic effects of BMPs in tumors with repressed
BMPR1B expression (Piccirillo et al., 2006).
In summary, we have identified a human glioblastoma TSC/
TIC, representative of a subset of primary human GBMs, that
appears to be very similar to a very early embryonic NSC but is
apparently blocked from further stem cell development and dif-
ferentiation though an aberration in the BMP signaling pathway.
Forced expression of methylated-promoter-repressed BMPR1B
restores normal differentiation capacity of the TSC/TICs halting
further proliferation and inducing terminal differentiation of the
TSC/TICs. We provide here an example of a temporally
Cancer Cell
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tal block to differentiation contributing to the pathogenesis of
a human tumor. Not only will such insights pave the way for
a more thorough understanding of TSC biology, but they also
identify BMPR1B as a promising molecular target and open the
potential for targeted therapeutic approaches for agents that
can induce TSC terminal differentiation.
EXPERIMENTAL PROCEDURES
Human and Mouse Tissues
Following informed consent, tumor samples classified as glioblastoma based
on World Health Organization (WHO) criteria were obtained from patients un-
dergoing surgical treatment at the NIH in accordance with the appropriate
Institutional Review Boards (Kleihues et al., 2002). Procedures regarding de-
rivation of TICs were described previously (Lee et al., 2006a). Time-pregnant
Swiss-Webster mice were used to isolate NSCs from various gestational
stages. NSCs isolated from E10 to E11 embryos were cultured in the presence
of FGF2 (10 ng/ml) without EGF. All mice experiments were performed accord-
ing to NIH guidelines of the Animal Use and Care Committees.
Antibodies for Immunohistochemistry and Western Blot Analysis
The following antibodies were used: GFAP, S100b (Dako), TuJ1 (Covance),
BrdU (Roche), STAT3 (Upstate), PY705-STAT3, PS727-STAT3, PS-SMAD1/
5/8, SMAD1 (Cell signaling), BMPR1A, BMPR1B, Sox2 (R&D systems), EZH2
(Cell signaling and Upstate), b-actin (Santa Cruz Biotechnology), and Human
ribonucleoprotein (1281, Chemicon).
Intracranial Tumor Cell Injection into SCID Mice
An intracranial orthotropic model was utilized for evaluation of TIC tumorige-
nicity (Uchida et al., 2000). 0308 cells or 0308-BMPR1B-cells were dissociated
and resuspended in 2 ml of HBSS. One hundred thousand cells, as determined
by trypan blue dye exclusion, were injected stereotactically into the lateral ven-
tricles of cryoanesthetized neonatal SCID mice at postnatal day 1. Following
injection, neonatal mice were returned to their mother and allowed to grow
to adulthood. There was no injection-procedure-related animal lethality. The
animals were killed at given time points for the analysis of tumor histology
and immunohistochemistry. Brains were perfused with 4% paraformaldehyde
by cardiac perfusion and further fixed at 40C overnight.
Chromatin Immunoprecipitation
Chip assays were performed by manufacturer’s protocol (Chip-It Express,
Active Motif) with enzymatic DNA shearing. Antibodies used for Chip assay
include EZH2 (Upstate) and DNMT1 (Active Motif). For negative and positive
control of Chip assay, a RNA polymerase II antibody and a negative control
IgG antibody were used (Chip-IT control kit).
Bisulfite DNA Modification and PCR Sequencing
Bisulfite DNA modification was essentially performed by manufacturer’s
instruction (Chemicon and Active Motif). After PCR using chemically modified
DNA as templates, PCR products were ligated into TOPO PCR cloning vector
(Invitrogen) and then used for transformation of E. Coli. The following PCR
primers were used: 50-GGAGGTTTTTTGGAAATTTTTTTAA-30 and 50- CCTCT




The Supplemental Data include eleven supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/1/69/
DC1/.
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